Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193114 | 0.70 | CACNA1D (0.35) | MAPTCACNA1D | |
| SCHEMBL6694686 | 0.69 | CACNA1D (0.30) | CACNA1D | |
| SCHEMBL7115170 | 0.66 | — | — | |
| SCHEMBL4659688 | 0.62 | POLB (0.38) | MAPTTSHR | |
| SCHEMBL10454797 | 0.60 | GSK3B (0.33) | TSHR | |
| Methane SCHEMBL21996436 | 0.60 | — | — | |
| SCHEMBL365626 | 0.59 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL6236368 | 0.59 | MAPT (0.35) | MAPTTSHR | |
| SCHEMBL8736494 | 0.58 | KDM1A (0.33) | CHRNA7 | |
| SCHEMBL7068638 | 0.57 | ATM (0.33) | MAPTTSHRCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324140-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | MAPT 4737/4885TSHR 57/4885CACNA1D 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.